Q-omics provides the consensus-scored MTSS2 profile across patient tissues and cancer cell-line models. MTSS2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MTSS2 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, MTSS2 RNA expression shows 18,772 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, THCA, and TGCT as cancer lineages where MTSS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTSS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTSS2 survival associations across molecular data types. MTSS2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTSS2 RNA expression–survival associations across cancer types. High MTSS2 expression shows unfavorable associations in MESO, KIRP, BRCA and ACC, but favorable associations in LGG and UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MTSS2 RNA expression.
This table summarizes MTSS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MTSS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTSS2 shows lower tumor expression in STAD and higher tumor expression in THCA, KICH, LIHC, COAD and LUAD. The THCA box plot shows higher MTSS2 RNA expression in tumor versus normal tissue (log2 FC = +0.557, t-test p < 0.001).
This table shows molecular features associated with MTSS2 in patient tissues and cancer cell lines. In patient samples, MTSS2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MTSS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
